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ABSTRACT
Introduction: Glycosylated haemoglobin level (HbA1c)
is an indicator of the average blood glucose
concentrations over the preceding 2–3 months and is
used as a convenient and well-known biomarker in
clinical practice. Currently, epidemiological evidence
suggests that HbA1c level is an independent risk factor
for cardiovascular events such as myocardial infarction,
stroke, coronary heart disease and heart failure. This
protocol aim is to conduct a systematic review and
meta-analysis to determine relationships of HbA1c
levels with cardiovascular outcomes and cause of
death, and to analyse the range of HbA1c levels that is
a predictor of cardiovascular disease and/or mortality
based on data from published observational studies.
Methods and analysis: The search will be
conducted using Medline, EMBASE, Cochrane Central
Register of Controlled Trials, Cochrane Database of
Systematic Reviews, and Web of Science databases
from their inception. Observational studies written in
Portuguese, Spanish or English will be included. The
Quality In Prognosis Studies tool will be used to
assess the risk of bias for the studies included in the
systematic review or meta-analysis. HRs for
cardiovascular outcomes and causes of death with
95% CIs will be determined as primary outcomes.
Subgroup analyses will be performed based on
cardiovascular outcomes, cause of death studied,
and type of population included in the studies.
Ethics and dissemination: This systematic review
will synthesise evidence on the potential of using HbA1c
level as a prognostic marker for cardiovascular disease
outcomes and/or mortality. The results will be
disseminated by publication in a peer-reviewed journal.
Ethics approval will not be needed because the data used
for this systematic review will be obtained from published
studies and there will be no concerns about privacy.
Trial registration number: PROSPERO
CRD42015032552.
INTRODUCTION
Cardiovascular disease (CVD) is a chronic
disorder that develops insidiously throughout
an individual’s life and usually has pro-
gressed to an advanced stage by the time
symptoms occur.1 The percentage of all
deaths due to CVD before the age of
75 years in Europe is 42% in women and
38% in men.2 CVD, especially coronary heart
disease, is the leading cause of premature
death worldwide.3
In 2007, The Reynolds Risk Score for pre-
dicting CVD risk was developed, which incor-
porates information on glycosylated
haemoglobin (HbA1c), but this score was
only used in people with known diabetes.4 In
2010, the American College of Cardiology
Foundation/American Heart Association
Task Force on Practice Guidelines consid-
ered HbA1c level to be an appropriate index
for CVD risk assessment in asymptomatic
adults without a diagnosis of diabetes.5
Finally, the Canadian Cardiovascular Society
proposed that CVD risk could be stratiﬁed by
measuring levels of fasting plasma glucose,
HbA1c, or both.6
HbA1c level is an indicator of the average
blood glucose concentrations over the preced-
ing 2–3 months and is used as a convenient
and well-known biomarker in clinical prac-
tice.7 8 Epidemiological evidence suggests that
Strengths and limitations of this study
▪ This review of evidence will be useful to improve
future research on HbA1c level as a prognostic
marker for cardiovascular disease outcomes and/
or mortality.
▪ Study selection, data extraction and quality
assessment will be performed independently by
two researchers.
▪ Limitations and strengths will be discussed in
our review, and the results will be put into
context with other studies in the field.
▪ Different population-based studies can be a source
of variable quality and heterogeneity between
studies and may limit the quality of the evidence of
this meta-analysis and systematic review.
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HbA1c level is an independent risk factor for cardiovascu-
lar events.9 There is also evidence that the association of
HbA1c level with mortality from all causes and CVD can
be found at lower levels than the diabetic threshold.10 A
meta-analysis showed that HbA1c level is an independent
predictor of mortality in patients with coronary artery
disease without established diabetes but not in those with
established diabetes.11
Currently, the association between chronic hypergly-
caemia and cardiovascular complications is not well
deﬁned. Several observational studies have demonstrated
that a higher HbA1c level is associated with increased
risk of CVD and death.9 12 13 Thus, an elevated HbA1c
level might contribute to the development of CVD, but
the association between HbA1c level and the risk of
CVD and mortality in the general population remains
unclear. Therefore, this protocol aims to present a clear
and transparent procedure for systematically reviewing,
evaluating and summarising existing information on the
relationship of HbA1c level with CVD and death, which
could guide clinical decision making in further treat-
ment strategies and also inform and facilitate future
intervention research.
OBJECTIVE
The aim of this protocol study is to establish a transpar-
ent and clear methodology for conducting a systematic
review and meta-analysis aimed to (i) determine the
relationship between HbA1c level and cause of death
and cardiovascular outcomes based on data from obser-
vational studies, and (ii) analyse what level of HbA1c is a
predictor of CVD and/or mortality.
METHODS AND ANALYSIS
Review design
This protocol was developed based on the Preferred
Reporting Items for Systematic Reviews and Meta-analyses
Protocols (PRISMA-P)14 and was registered with
PROSPERO (Registration number CRD42015032552). The
MOOSE15 (Meta-analysis of observational studies in epi-
demiology: a proposal for reporting), PRISMA16 and
Cochrane Collaboration Handbook17 will be used to guide
the review methods.
Literature review
The literature search will be conducted using Medline
(via PubMed), EMBASE, Cochrane Central Register of
Controlled Trials, Cochrane Database of Systematic
Reviews, and Web of Science databases from the date of
their inception until August 2016. Study records will be
managed with the Mendeley reference manager.
The following search terms will be combined using
Boolean operators: glycosylated haemoglobin, HbA1c,
haemoglobin levels, glycated haemoglobin, haemoglobin
A1c, cardiovascular, cardiovascular disease, coronary
heart disease, heart failure, stroke, peripheral arterial
disease, cardiovascular events, coronary artery disease,
myocardial infarction, cardiovascular outcomes, mortality,
all-cause mortality, cardiovascular mortality, cause-speciﬁc
mortality, death, cardiovascular death, observational study,
cohort study and population-based (table 1).
Previous systematic reviews and meta-analyses, and
relevant references included in the selected studies, will
be screened as supplemental sources.
Inclusion/exclusion criteria for study selection
Studies on HbA1c level and cardiovascular outcomes
retrieved in the literature search that meet the following
criteria will be included: (i) prospective or retrospective
observational studies; (ii) studies that observed the follow-
ing cardiovascular outcomes: myocardial infarction, stroke,
major adverse cardiovascular events (MACE), coronary
heart disease and heart failure; (iii) reports of all-cause
mortality and/or cardiovascular mortality; (iv) outcomes
measured using univariate and multivariate Cox propor-
tional hazards models; (v) population of adults aged 18
or older with any restriction on the race, gender or dia-
betic status; and (vi) studies published in Portuguese,
Spanish or English.
The process of identifying, screening of studies and
inclusion or exclusion of those studies is shown in the
PRISMA ﬂow chart (ﬁgure 1).
Study selection and data extraction
Two reviewers will independently check titles and
abstracts to identify eligible studies according to the
inclusion criteria. Then the full manuscripts of the iden-
tiﬁed studies will be examined. Finally, two reviewers will
check the included and excluded studies and verify the
reasons why they were included/excluded. Any discrep-
ancies will be resolved by discussion; a third reviewer will
be asked in cases of disagreement.
Two authors will independently extract the data on
author information, year of publication, design of study,
country, study project name and year of data collection,
number and age of participants, population character-
istics (diabetic or non-diabetic), methods used for
HbA1c test certiﬁed by National Glycohemoglobin
Standardization Program (NGSP), number of cardiovas-
cular events, level of HbA1c used as the reference, and
the HR for each HbA1c level (table 2).
Any disagreement will be resolved by discussion to
reach a consensus. When necessary, authors of the
potential included studies will be contacted to obtain
any missing information.
Assessment of the risk of bias in the included studies
After blinding of two independent researchers to the
author, title and year of publication of the included
studies, the methodological quality will be assessed by
the Quality in Prognosis Studies (QUIPS) tool.18 Any dis-
agreement in the assessment of the risk of bias will be
discussed to reach a consensus. A third reviewer will
make the ﬁnal decision if a consensus is not reached.
The QUIPS tool involves the use of six domains for the
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risk of bias: study participation (sampling bias), study
attrition (attrition bias), prognostic factor measurement,
outcome measurement (ascertainment bias), confound-
ing measurement and accounting, and analysis and
reporting. Studies will be considered to have a low, mode-
rate or high risk of bias according to scores of 5–6, 3–4
or 1–2, respectively, for the six bias domains.
Statistical analysis
The researchers will create tables to summarise the
characteristics of the included studies and any important
questions related to the aim of this systematic review.
The reviewers will determine whether a meta-analysis is
possible after the data have been extracted. At least
ﬁve observations addressing HR for cardiovascular out-
comes and mortality will be required to conduct a
meta-analysis. If it is possible to carry out a meta-analysis,
Stata 14 software will be used to combine the extracted
HR with 95% CIs using an inverse variance model. We
will compare adjusted and unadjusted estimates separ-
ately for each outcome. A ﬁxed-effects model will be
used if there is no evidence of heterogeneity; otherwise,
a random-effects model will be used.19 For HbA1c levels,
we will group studies by similar cut-off points to obtain
meta-analysis results for each cut-off point whenever
possible. We will use generalised least squares regression
models to assess the pooled dose–response relation
between HbA1c and CVD outcomes across prospective
cohort studies that have heterogeneous categorisations
of HbA1c.20 Each meta-analysis will be summarised by
the pooled HR and 95% CIs. Studies providing insufﬁ-
cient data to perform the analyses will be omitted from
the data synthesis. The heterogeneity of the studies will
be assessed with an I2 statistic. Usually, I2 values of <25%,
25–50% and >50% are considered to represent small,
medium and large amounts of heterogeneity, respect-
ively.21 If a meta-analysis is not possible, we will under-
take a narrative synthesis. Finally, publication bias will
be visually evaluated using a funnel plot, as well as with
the method proposed by Egger.22 The strength of the
body of evidence will be evaluated using the Grading
of Recommendations Assessment, Development and
Evaluation (GRADE) tool.23
Subgroup analyses and meta-regression
Subgroup analyses and meta-regression will be performed
based on the cardiovascular outcomes (myocardial
infarction, stroke, MACE, coronary heart disease, heart
failure), cause of death studied (all causes of mortality
or cardiovascular mortality), type of population included
Table 1 Search strategy for Medline
“glycosylated haemoglobin”
OR
“HbA1c”
OR
“haemoglobin levels”
OR
“glycated haemoglobin”
OR
“haemoglobin A1c”
AND Cardiovascular
OR
‘cardiovascular disease’
OR
‘coronary heart disease’
OR
‘heart failure’
OR
Stroke
OR
‘peripheral arterial disease’
OR
‘cardiovascular events’
OR
‘coronary artery disease’
OR
‘myocardial infarction’
OR
‘cardiovascular outcomes’
OR
mortality
OR
‘all-cause mortality’
OR
‘cardiovascular mortality’
OR
‘cause-specific mortality’
OR
death
OR
‘cardiovascular death’
AND ‘observational study’
OR
‘cohort study’
OR
‘population-based
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in the studies (diabetic, prediabetic or non-diabetic), or
the age of the study participants (young adults aged
18–35 years, middle-aged adults aged 36–55 years, or
older adults aged older than 55 years), because these may
be major factors causing heterogeneity. Furthermore,
design of the study and QUIPS score will be considered
for additional subgroup analyses.
Sensitivity analysis
Sensitivity analyses will be performed by excluding the
included studies from the analysis one by one and com-
paring the results.
DISCUSSION
The utility of HbA1c level as a prognostic marker for
CVD outcomes and/or mortality is currently a source of
controversy in the medical literature. Therefore, we will
conduct a systematic review to identify what HbA1c level
might be able to predict CVD outcome and mortality.
There is currently no consensus on what percentages
should be used to determine the level of heterogeneity
in categorical terms. Therefore, in this study, we will use
the deﬁnition suggested by Higgins and Thompson21 to
indicate that there is heterogeneity when the I2 value is
>50%.
Possible limitations of this research are publication
bias, information bias, poor statistical analyses and inad-
equate reporting of methods and ﬁndings of the
primary studies.24 However, it is important to summarise
the information available on this issue. To overcome
these limitations, we will follow the recommendations
included in the MOOSE, PRISMA and Cochrane
Figure 1 Literature search PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) consort diagram.
Table 2 Characteristics of studies included in the systematic review and/or meta-analysis
Reference Design Country
Study/year
of data
collection Age n
n
cardiovascular
events
HbA1c
method
HbA1c
reference
level
HR for
HbA1c
levels
Author
information
and year of
publication
Design
of the
study
Country Study
project
name and
year of
data
collection
Age of
participants
Number of
participants
Number of
cardiovascular
events
Methods
used for
HbA1c
test
certified
by NGSP
Level of
HbA1c
used as
the
reference
HR for
each
HbA1c
level
HbA1c, glycosylated haemoglobin; NGSP, National Glycohemoglobin Standardization Program.
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Collaboration Handbook. According to the Cochrane
Prognosis Methods Group, we will use the QUIPS tool to
assess the quality of the included studies.18
There have already been numerous studies on the use
of HbA1c level as a prognostic marker for CVD outcome
and mortality, but the individual studies have been con-
troversial, so there is uncertainty regarding its use. It is
therefore necessary to conduct a systematic review to
provide a global overview of the current literature and to
improve future research on this topic. This protocol pro-
vides a clear and structured procedure for maximising
the extraction of relevant information and providing
summarised information on the importance of HbA1c
levels for controlling the risk of CVD outcomes and
mortality.
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